Thomas Areschoug
Corporate Officer/Principal bei XINTELA AB
Profil
Thomas Areschoug was the founder of Minervax ApS, a company founded in 2010 where he held the title of Director.
He is currently working as the Chief Business Officer at Xintela AB since 2017.
In the past, he worked as the Manager-Business Development at Invest in Skane AB.
Aktive Positionen von Thomas Areschoug
| Unternehmen | Position | Beginn |
|---|---|---|
| XINTELA AB | Corporate Officer/Principal | 01.03.2017 |
Ehemalige bekannte Positionen von Thomas Areschoug
| Unternehmen | Position | Ende |
|---|---|---|
Invest in Skane AB
 Invest in Skane AB Miscellaneous Commercial ServicesCommercial Services Invest in Skane AB provides organization consulting services. The private company is based in Skane, Sweden. | Corporate Officer/Principal | - |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Founder | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| XINTELA AB | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Invest in Skane AB
Invest in Skane AB Miscellaneous Commercial ServicesCommercial Services Invest in Skane AB provides organization consulting services. The private company is based in Skane, Sweden. | Commercial Services |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
